Please assess the completion status of the following clinical trial:

Trial Title: Amniotic Fluid Tandem Mass Spectrometry for Pregnancies Complicated by NIH and Severe Symmetrical IUGR

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
NIH Inclusion Criteria:~* Singleton gestation~* 18 years of age or older~* Excess extracellular fluid in at least two fetal sites as noted by ultrasound: abdomen (ascites), the chest (pleural and pericardial effusions), the skin (edema \> 5mm), the amniotic cavity (polyhydramnios), and the placenta (thickening \> 6cm)~* NIH diagnosis \> 15w0d gestation~* Diagnostic amniocentesis performed at \> 15w0d gestation~NIH Exclusion Criteria:~* Immune-mediated hydrops fetalis as diagnosed by maternal red cell antigens and fetal anemia suspected by middle cerebral artery doppler ultrasound and/or confirmed by percutaneous umbilical blood sampling~* Structural anomaly identified by ultrasound~* Chromosomal aneuploidy~* Multiple gestations~IUGR Inclusion Criteria:~* Singleton gestation~* 18 years of age or older~* Severe symmetrical IUGR defined as a \> 3 week lag of all fetal ultrasound measurements (biparietal diameter, head circumference, abdominal circumference, and femur length)~* IUGR diagnosis between 24-32 weeks gestation~* Diagnostic amniocentesis performed prior to 32 weeks gestation~IUGR Exclusion Criteria:~* Asymmetrical IUGR~* Structural anomaly identified by ultrasound~* Chromosomal aneuploidy~* Multiple gestations

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- NIH/SSIUGR fetuses (Type: None): Group 1 includes pregnancies complicated by a fetus with either Non-Immune Hydrops or Severe Symmetrical IUGR.
- Control-Normal fetus (Type: None): Group 2 includes all normally appearing fetuses on U/S who will be having a diagnostic amniocentesis as part of their routine care.

Based on this trial design, predict the completion outcome and termination type (if applicable).